More Videos
SPECIAL REPORT
MOST SHARED
- UK Economy Turned, Inflation to Spike: BoE Economist
- Cisco Has 84% of Tandberg, Won't Extend Bid
- Kohlberg Kravis Bidding for Morgan Stanley's CICC Stake
- Case Closed but Woods Scrutiny Continues
- Australia Regulator Opposes Caltex-Exxon Deal
- Keeping America Great
- GE, Comcast Complete Deal Over NBC Universal: Source
- Australia Parliament Rejects Carbon Trade Laws
- Look Ahead: Markets Count Down to US Jobs Report
- Treasury Assistance Comes at High Price For GM
- Unemployment to Peak at 10.5%: Moody's Economist
- 8 Stocks to Gain on Obama's Afghan Plan: Analysts
- BofA On Proposed Changes In The Housing Bailout Program
- The Future of The Media Landscape
- November Auto Sales Muddle Along
- Busch: What Obama Won't Say Tonight
- Stick with Equities—Avoid Emerging Markets: Laszlo Birinyi
- Pfizer Chomps On A Carrot
- Mortgage Applications Up as Rates Continue to Decrease
- Wal-Mart Targets Video Games with Latest Price Cuts
- 'Black Swan' Shuns Public Life Because of Bernanke
- Dubai World To Meet with Creditors Next Week
- FHA to Toughen Mortgage Rules in Lenders Crackdown
- Obama to Send More Troops; Seeks Afghanistan Exit
- GM Removes CEO Henderson; Whitacre Is Interim Chief
- UK Economy Turned, Inflation to Spike: BoE Economist
- Who Were the Biggest Winners And Losers This Year?
PHARMA'S MARKET VIDEO
RSS FEED
Pharma's Market
Text Size 
These days, it's not uncommon to see campaigns calling for the withdrawal of a drug from the market because of safety concerns. That's why this campaign urging the approval of a drug is extraordinary. Proponents of Dendreon's [DNDN
Loading...
()
] Provenge took out this no-frills, half-page ad in the opinion section of Sunday's edition of "The Washington Post".
A patchwork group of about 150 investors, patients, activists, advocates, etc. came up with a total of 24-grand to buy the space. They claim to have found each other and to have raised the money over three months on the Dendreon message board at Investor Village. I heard from Dendreon this morning and they say they knew nothing about the ad.
The copy recaps the Provenge clinical trial results, the FDA Advisory Committee vote and subsequent FDA decision to delay a decision on the drug. At the bottom, in boldface, there's an appeal to "Please ask your Senators and Representatives to demand a reconsideration (by the FDA). The FDA wants to wait as much as 2-3 years for more data. Men dying of prostate cancer don't have that luxury. All citizens...should immediately contact Congressional representatives, urging them to ensure this travesty is reversed."
Arnie Mass, a Dendreon investor from Chicagoland who was the apparent ringleader of the group behind the ad, says, "This is democracy in action. It's a grassroots development. And we want the senators and congresspeople to hear this, so that they might take action. We are activists and this is how the story has to get out." Mass says he has owned DNDN shares for about four years and, so far, he claims to have broken even on the stock.
Dendreon says the FDA will possibly accept interim data from an ongoing, large clinical trial to consider approval of Provenge. That info won't be available until the middle or second half of next year. The company says the agency could also wait for the complete data to come in before making a decision and those results aren't expected for another two to three years. Last week, Dendreon revealed the SEC is conducting an informal inquiry into the Provenge saga.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes